Novel ATP-Competitive Kinesin Spindle Protein Inhibitors
Citations Over TimeTop 11% of 2007 papers
Abstract
Kinesin spindle protein (KSP), an ATPase responsible for spindle pole separation during mitosis that is present only in proliferating cells, has become a novel and attractive anticancer target with potential for reduced side effects compared to currently available therapies. We report herein the discovery of the first known ATP-competitive inhibitors of KSP, which display a unique activity profile as compared to the known loop 5 (L5) allosteric KSP inhibitors that are currently under clinical evaluation. Optimization of this series led to the identification of biphenyl sulfamide 20, a potent KSP inhibitor with in vitro antiproliferative activity against human cells with either wild-type KSP (HCT116) or mutant KSP (HCT116 D130V). In a murine xenograft model with HCT116 D130V tumors, 20 showed significant antitumor activity following intraperitoneal dosing, providing in vivo proof-of-principle of the efficacy of an ATP-competitive KSP inhibitor versus tumors that are resistant to the other known KSP inhibitors.
Related Papers
- → Comparison of an in vitro method and an in vivo method of Giardia excystation(1992)23 cited
- → IN VITRO SPECIFICITY AND IN VIVO ACTIVITY OF ANTIMACROPHAGE SERUM(1974)4 cited
- → Actin Organization as an in Vitro Assay for Tumorigenicity(1982)2 cited
- [Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels].(1988)
- The release of the marked insulin J125 from ointment in vitro and in vivo.(1993)